title: [New options in the therapy for neovascular age-related macular degeneration: critieria for repeat treatment in anti-VEGF therapy - current supplementary statement of the Retinological Society, The German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany].
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D005858:Germany; D006801:Humans; D008268:Macular Degeneration / Q000150:complications* / Q000188:drug therapy*; D015861:Retinal Neovascularization / Q000150:complications* / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000008:administration & dosage*
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A